Drug
Ingavirin, 90 mg, Capsules
Ingavirin, 90 mg, Capsules is a pharmaceutical drug with 2 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
1
50%
Ph phase_2
1
50%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(1)
Completed(1)
Detailed Status
Recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (50.0%)
Phase 31 (50.0%)
Trials by Status
recruiting150%
completed150%
Recent Activity
1 active trials
Showing 2 of 2
recruitingphase_2
Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.
NCT07420985
completedphase_3
Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19
NCT05216497
Clinical Trials (2)
Showing 2 of 2 trials
NCT07420985Phase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.
NCT05216497Phase 3
Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2